134 related articles for article (PubMed ID: 6607783)
1. Disturbance of 6-mercaptopurine metabolism by cotrimoxazole in childhood lymphoblastic leukaemia.
Rees CA; Lennard L; Lilleyman JS; Maddocks JL
Cancer Chemother Pharmacol; 1984; 12(2):87-9. PubMed ID: 6607783
[TBL] [Abstract][Full Text] [Related]
2. Childhood lymphoblastic leukaemia: sex difference in 6-mercaptopurine utilization.
Lilleyman JS; Lennard L; Rees CA; Morgan G; Maddocks JL
Br J Cancer; 1984 Jun; 49(6):703-7. PubMed ID: 6587901
[TBL] [Abstract][Full Text] [Related]
3. The effect of cotrimoxazole on the absorption of orally administered 6-mercaptopurine in the rat.
Burton NK; Aherne GW
Cancer Chemother Pharmacol; 1986; 16(1):83-4. PubMed ID: 3484383
[TBL] [Abstract][Full Text] [Related]
4. 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia.
Schmiegelow K; Bruunshuus I
Cancer Chemother Pharmacol; 1990; 26(4):288-92. PubMed ID: 2369793
[TBL] [Abstract][Full Text] [Related]
5. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia.
Lennard L; Rees CA; Lilleyman JS; Maddocks JL
Br J Clin Pharmacol; 1983 Oct; 16(4):359-63. PubMed ID: 6578834
[TBL] [Abstract][Full Text] [Related]
6. The effect of folate supplements on 6-mercaptopurine remission maintenance therapy in childhood leukaemia.
Lennard L; Lilleyman JS; Maddocks JL
Br J Cancer; 1986 Jan; 53(1):115-9. PubMed ID: 3456241
[TBL] [Abstract][Full Text] [Related]
7. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia.
Lilleyman JS; Lennard L
Lancet; 1994 May; 343(8907):1188-90. PubMed ID: 7909868
[TBL] [Abstract][Full Text] [Related]
8. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
[TBL] [Abstract][Full Text] [Related]
9. 6-Mercaptopurine: apparent lack of relation between prescribed dose and biological effect in children with leukaemia.
Herber S; Lennard L; Lilleyman JS; Maddocks J
Br J Cancer; 1982 Jul; 46(1):138-41. PubMed ID: 6954968
[No Abstract] [Full Text] [Related]
10. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
Erb N; Harms DO; Janka-Schaub G
Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
[TBL] [Abstract][Full Text] [Related]
11. Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells.
Lennard L; Maddocks JL
J Pharm Pharmacol; 1983 Jan; 35(1):15-8. PubMed ID: 6131958
[TBL] [Abstract][Full Text] [Related]
12. Influence of co-trimoxazole on methotrexate pharmacokinetics in children with acute lymphoblastic leukemia.
Beach BJ; Woods WG; Howell SB
Am J Pediatr Hematol Oncol; 1981; 3(2):115-9. PubMed ID: 6975580
[TBL] [Abstract][Full Text] [Related]
13. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
[TBL] [Abstract][Full Text] [Related]
14. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Hedeland RL; Hvidt K; Nersting J; Rosthøj S; Dalhoff K; Lausen B; Schmiegelow K
Cancer Chemother Pharmacol; 2010 Aug; 66(3):485-91. PubMed ID: 19956952
[TBL] [Abstract][Full Text] [Related]
15. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.
Lennard L; Lilleyman JS; Van Loon J; Weinshilboum RM
Lancet; 1990 Jul; 336(8709):225-9. PubMed ID: 1973780
[TBL] [Abstract][Full Text] [Related]
16. Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance?
Davies HA; Lennard L; Lilleyman JS
BMJ; 1993 May; 306(6887):1239-40. PubMed ID: 8499854
[No Abstract] [Full Text] [Related]
17. Are children with lymphoblastic leukaemia given enough 6-mercaptopurine?
Lennard L; Lilleyman JS
Lancet; 1987 Oct; 2(8562):785-7. PubMed ID: 2888996
[No Abstract] [Full Text] [Related]
18. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism.
Bo J; Schrøder H; Kristinsson J; Madsen B; Szumlanski C; Weinshilboum R; Andersen JB; Schmiegelow K
Cancer; 1999 Sep; 86(6):1080-6. PubMed ID: 10491537
[TBL] [Abstract][Full Text] [Related]
19. Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations.
Lennard L; Keen D; Lilleyman JS
Clin Pharmacol Ther; 1986 Sep; 40(3):287-92. PubMed ID: 3461899
[TBL] [Abstract][Full Text] [Related]
20. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.
Lennard L; Gibson BE; Nicole T; Lilleyman JS
Arch Dis Child; 1993 Nov; 69(5):577-9. PubMed ID: 8257179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
